KPIs & Operating Metrics(New)
Growth Metrics

Amgen (AMGN) Non-Current Deferred Tax Liability (2016 - 2026)

Amgen has reported Non-Current Deferred Tax Liability over the past 13 years, most recently at $1.3 billion for Q1 2026.

  • For Q1 2026, Non-Current Deferred Tax Liability fell 10.99% year-over-year to $1.3 billion; the TTM value through Mar 2026 reached $1.3 billion, down 10.99%, while the annual FY2025 figure was $1.4 billion, 15.47% down from the prior year.
  • Non-Current Deferred Tax Liability for Q1 2026 was $1.3 billion at Amgen, down from $1.4 billion in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $2.4 billion in Q4 2023 and troughed at $11.0 million in Q4 2022.
  • A 5-year average of $1.5 billion and a median of $1.5 billion in 2025 define the central range for Non-Current Deferred Tax Liability.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: skyrocketed 21300.0% in 2023 and later plummeted 31.35% in 2024.
  • Year by year, Non-Current Deferred Tax Liability stood at $11.0 million in 2022, then skyrocketed by 21300.0% to $2.4 billion in 2023, then plummeted by 31.35% to $1.6 billion in 2024, then fell by 15.47% to $1.4 billion in 2025, then dropped by 1.61% to $1.3 billion in 2026.
  • Business Quant data shows Non-Current Deferred Tax Liability for AMGN at $1.3 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.5 billion in Q3 2025.